BLISSGVS
OVERVALUEDBliss GVS Pharma Limited
Pharma · NSE
↓ 34.2% vs fair value
52W Low
₹108
+118.7% from low
52W High
₹244
-3.0% from high
Valuation Gauge
Current Price
₹237
Fair Value
₹176
Fair Value Analysis
₹176
Based on free cash flow projections and earnings growth potential for Pharma sector companies | Sector-cheap: P/E at 24th percentile vs sector peers. | CAUTION: ROCE declining (latest 11.2%) — returns on capital are falling; verify this isn't a value trap. | COVID-resilient: PAT dropped from ₹127Cr (FY2019) to ₹23Cr (FY2022) during COVID but has fully recovered.
Cash Flow Analysis
38% weight
Growth Valuation
63% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 10.2% is acceptable for Pharma sector (benchmark: 18%)
Debt & Leverage
D/E ratio of 0.0x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 22.7x trades at a 46% discount to Pharma sector median (42x) — attractively valued
Cash Flow
FCF margin of 3.7% — thin cash generation, watch capex trends
Earnings Growth
5yr EPS CAGR of 77.6% is well above the Pharma sector average of 15.3% — strong growth
Dividend
Dividend yield of 0.4% is symbolic — low but positive
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
1.2%
Free cash flow / market cap
Revenue Growth (YoY)
+3.8%
Year-on-year revenue change
Profit Growth (YoY)
-3.9%
Year-on-year PAT change
Operating Cash Flow
₹106 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹10.3
P/E Ratio
22.7x
P/B Ratio
2.4x
ROE
10.2%
ROCE
11.7%
Debt / Equity
0.04x
Beta
0.82
Div Yield
0.4%
FCF (Cr)
₹30 Cr
Revenue (Cr)
₹802 Cr
EPS Growth 5Y
77.6%
Mkt Cap (Cr)
₹2,479 Cr
52W High
₹243.9
52W Low
₹108.1
Book Value/Share
₹99.7
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹868 Cr | ₹141 Cr | 16.0% | ₹114 Cr | ₹10.33 |
| 2025-03-31 | ₹810 Cr | ₹127 Cr | 16.0% | ₹90 Cr | ₹8.00 |
| 2024-03-31 | ₹770 Cr | ₹151 Cr | 20.0% | ₹82 Cr | ₹7.21 |
| 2023-03-31 | ₹752 Cr | ₹117 Cr | 16.0% | ₹77 Cr | ₹6.80 |
| 2022-03-31 | ₹747 Cr | ₹118 Cr | 16.0% | ₹23 Cr | ₹1.45 |
| 2021-03-31 | ₹577 Cr | ₹107 Cr | 18.0% | ₹74 Cr | ₹6.64 |
| 2020-03-31 | ₹689 Cr | ₹123 Cr | 18.0% | ₹95 Cr | ₹9.43 |
| 2019-03-31 | ₹899 Cr | ₹160 Cr | 18.0% | ₹127 Cr | ₹11.99 |
| 2018-03-31 | ₹815 Cr | ₹197 Cr | 24.0% | ₹89 Cr | ₹5.70 |
| 2017-03-31 | ₹798 Cr | ₹203 Cr | 25.0% | ₹113 Cr | ₹7.95 |
| 2016-03-31 | ₹547 Cr | ₹156 Cr | 29.0% | ₹100 Cr | ₹8.00 |
| 2015-03-31 | ₹407 Cr | ₹103 Cr | 25.0% | ₹61 Cr | ₹5.81 |
| 2014-03-31 | ₹345 Cr | ₹71 Cr | 21.0% | ₹41 Cr | ₹3.97 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86 | ₹469.7 | +81.7% | 7.3 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹79.5 | ₹237.8 | +66.6% | 19.6 | 5.2% | FAIRLY_VALUED |
Kilitch Drugs (India) Limited | ₹132.7 | ₹321 | +58.7% | 17.7 | 9.4% | UNDERVALUED |
Bal Pharma Limited | ₹69 | ₹147.5 | +53.2% | 12.8 | 12.6% | FAIRLY_VALUED |
Zydus Lifesciences | ₹868 | ₹1,502.2 | +42.2% | 17.6 | 19.9% | UNDERVALUED |
Natco Pharma | ₹1,030 | ₹1,597 | +35.5% | 11.8 | 18.0% | UNDERVALUED |
Jagsonpal Pharmaceuticals Limited | ₹190.6 | ₹275.2 | +30.7% | 30.8 | 20.1% | UNDERVALUED |
Lupin | ₹2,280 | ₹3,112 | +26.7% | 22.4 | 23.8% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant